Clinical trials: Healthy Normal Weight Women
Healhty, Overweight or Obesity
Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM1812 Injection Following Single and Multiple Subcutaneous Administration in Normal to Overweight or Obese But Otherwise Healthy Men and Women
This is a Phase 1, single-center, double-blind, placebo-controlled, dose-escalation study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM1812…
- Trial name
- NCT07224399
- Testing
- BGM1812
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Chronic Kidney Disease, Renal Impairment
A Study to Learn How the Study Treatment BAY3283142 Taken as Single Dose by Mouth Moves Into, Through, and Out of the Body, How Safe it is, and How it Affects the Body in Participants With Reduced Kidney Function Compared to Participants With Normal Kidney Function of Similar Age, Gender, and Weight
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD). The kidneys filter extra water and waste out of the blood and make urine.
- Conditions
- Chronic Kidney Disease, Renal Impairment, Healthy Volunteers
- Trial name
- NCT05515432
- Testing
- Single oral dose of BAY3283142 IR (immediate release) tablet
- Where
- Germany
- Volunteers
- 45 people
- Sponsor
- Bayer